The phase III ShortHER trial compared the efficacy of different durations of trastuzumab therapy for patients with HER2-positive breast cancer. Long-term results were recently published by Conte et al in the Journal of Clinical Oncology.
Question 1 of 5
Compared to 1 year of treatment with trastuzumab, what was the 10-year disease-free survival seen with 9 weeks of treatment with trastuzumab for patients with HER2-positive breast cancer?
